The proportion and count of circulating TFH2 and ICOS + cTFH cells exhibited a decline in patients with allergic asthma who underwent treatment with ICS and an anti‐IgE mAb (omalizumab) [142–144]. The gene discussed is IGHE; the disease is allergic asthma.